Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > How does Accelerated Approval work

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jun 06, 2024 1:14pm

222 Views

Post# 36075733

RE:How does Accelerated Approval work

Endpoints reported today that OV company Replimmue "aims" for accelerated approval for their intratumorally delivered OV + nivolumab (Optivo) in the treatment of melanoma after reporting a 28.3% all subgroup overall response rates (ORR) in its RP1 IGNYTE Phase 1 clinical trial in PD-1 failed melanoma patients.

https://endpts.com/replimune-aims-for-accelerated-approval-of-melanoma-therapy-structures-upsized-476m-offering/

<< Previous

Bullboard Posts

Next >>

Stockhouse DealRoom opens new Australian opportunities